Haemonetics (NYSE: HAE) reported Q4 EPS of $0.61, $0.06 better than the analyst estimate of $0.55. Revenue for the quarter came in at $249.3 million versus the consensus estimate of $250.63 million.

GUIDANCE:

Haemonetics sees FY2020 EPS of $2.80-$3.00, versus the consensus of $2.89.

SHARE REPURCHASE PROGRAM The Company announced that its Board of Directors recently authorized the repurchase of up to $500 million of Haemonetics common shares over the next two years. This new share repurchase program will help to offset the dilutive impact of recent and future employee equity grants. The timing and amounts of activity under the repurchase program will be at management’s discretion with the intent of beginning activity under the program during fiscal 2020. In addition to this share repurchase activity, the Company’s capital allocation strategy continues to prioritize funding of planned internal investments to support the business as well as external opportunities to accelerate its long-term growth plans. Under the share repurchase program, the Company is authorized to repurchase, from time to time, outstanding shares of common stock in accordance with applicable laws on the open market, including under trading plans established pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in privately negotiated transactions. The actual timing, number and value of shares repurchased will be determined by the Company at its discretion and will depend on a number of factors, including market conditions, applicable legal requirements and compliance with the terms of loan covenants. The share repurchase program may be suspended, modified or discontinued at any time, and the C

For earnings history and earnings-related data on Haemonetics (HAE) click here.